A Win for Durvalumab Doublet in Muscle-Invasive Bladder Cancer
The chemo-sparing regimen also cut the risk of progression, recurrence, surgery failure or death by 49%, researchers reported.
- The VOLGA study shows a regimen combining AstraZeneca's Imfinzi and Astellas and Pfizer's Padcev for muscle-invasive bladder cancer reduced the risk of death by 42% compared to standard surgery.
- Thomas Powles of Barts Health NHS Trust noted that "Patients with muscle-invasive bladder cancer require life-changing bladder removal surgery," yet despite this, cancer returns in about half of patients, creating urgency for new options.
- The regimen reduced the risk of disease progression, recurrence, or death by 49%, with median event-free survival of 12.1 months for the control group; adding AstraZeneca's Imjudo delivered no added benefit.
- Published in the New England Journal of Medicine, the findings led Powles to state that "These practice-changing results support this approach as a patient-centric, potential new standard of care in this setting."
- ESMO commentator Michiel van der Heijden of the Netherlands Cancer Institute stated that "Data on ADCs plus immune checkpoint inhibitors in bladder cancer are now robust," though future investigations may clarify adjuvant Padcev benefit.
14 Articles
14 Articles
A Win for Durvalumab Doublet in Muscle-Invasive Bladder Cancer
(MedPage Today) -- Perioperative treatment with durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin (EV) significantly improved event-free survival (EFS) and overall survival (OS) compared with radical cystectomy in patients with muscle-invasive...
AstraZeneca Reports Improved Survival with Imfinzi and Enfortumab Vedotin in Phase III VOLGA Bladder Cancer Trial
Phase III analysis found a 49% reduction in event-free survival events and a 42% reduction in risk of death versus the comparator arm IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca has reported positive Phase III VOLGA results for perioperative Imfinzi (durvalumab) plus neoadjuvant … Read the full press release →
Giving immunotherapy and an antibody conjugate in conjunction with surgery improved survival in some patients with muscle-invasive bladder cancer, a phase 3 study shows. “Impressive results,” states a Swedish expert.
All'Esmo 2026 in progress in Madrid, Emiliano Tamburini, director of the Oncology department of the Cardinal Panico Hospital in Tricase (Lecce) comments on the results of the study Volga, dedicated to patients with muscle-invasive bladder cancer who cannot receive cisplatin chemotherapy. .The combination of durvalumab and enfortumab vedotin showed a reduction in the risk of... Continue reading L'articolo Esmo 2026, oncologist Tamburini, .....…
At ESMO 2026 in progress in Madrid, Emiliano Tamburini, director of the Oncology Department of the Cardinal Panico Hospital in Tricase (Lecce) comments on the results of the Volga study, dedicated to patients with muscle-invasive bladder cancer who cannot receive chemotherapy with cisplatin. “The combination of durvalumab and enfortumab vedotin has shown a reduction in the risk of recurrence or progression of the disease and the risk of death, o…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium









